NCT02144272 is a Phase 1 clinical trial of LY3114062 SC in Inflammatory Arthritis, sponsored by Eli Lilly and Company.

Who is sponsoring NCT02144272?

NCT02144272 is sponsored by Eli Lilly and Company.

What drugs are being tested in NCT02144272?

Interventions in NCT02144272: LY3114062 SC, Placebo, LY3114062 IV.

What condition does NCT02144272 study?

NCT02144272 studies Inflammatory Arthritis.

Is NCT02144272 still recruiting?

NCT02144272 is currently completed. Last updated 15 July 2015.

Last reviewed 2015-07-15 · How we verify

NCT02144272

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase 1 Single-Dose, Dose Escalation Study to Evaluate the Safety and Tolerability of LY3114062 in Subjects With Inflammatory Arthritis

Completed Phase 1 Last updated 15 July 2015

What this trial tests

Phase 1 trial testing LY3114062 SC in Inflammatory Arthritis in 41 participants. Completed in 1 June 2015.

Timeline

1 June 2014

Primary endpoint
1 May 2015

1 June 2015

Quick facts

Lead sponsor	Eli Lilly and Company
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	basic science
Enrollment	41
Start date	1 June 2014
Primary completion	1 May 2015
Estimated completion	1 June 2015
Sites	4 locations across Bulgaria, Georgia, Moldova, Romania

Drugs / interventions tested

LY3114062 SC — full drug profile →
Placebo
LY3114062 IV — full drug profile →

Conditions studied

Inflammatory Arthritis — all drugs for Inflammatory Arthritis →

Sponsor

Eli Lilly and Company — full company profile →

Who can join

Adults 18 to 65, any sex, with Inflammatory Arthritis. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

The Number of Participants with One or More Drug-Related Adverse Events
Time frame: Baseline to study completion (3 months)

Sponsor's own description

The main purpose of this study is to learn more about the safety of LY3114062 and to find out how well it is tolerated in participants with an inflammatory arthritis. The study will also investigate how the body processes the drug and how the drug affects inflammatory arthritis. The study is expected to last about 3 months.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Inflammatory Arthritis

Currently open trials in the same condition.

NCT07302074 — Understanding of Rare Inflammatory Arthritis in Comparison to Classical Inflammatory Arthritis : Tissular Observations a · NA · recruiting
NCT07278609 — The RheumSafer Study: Improving Medication Appropriateness in People With Rheumatic Conditions · recruiting
NCT06533423 — Effect of a Self-Management Intervention for Patients Newly Diagnosed With Inflammatory Arthritis: The NISMA Trial · NA · recruiting
NCT05715463 — Rheumatology-based Adaptive Intervention for Social Determinants and Health Equity · NA · active not recruiting
NCT05647577 — The Relationship Between Inflammatory ARTritis and CArdiac DIseAse · active not recruiting

Other Eli Lilly and Company trials

Trials by the same sponsor.

NCT07533006 — A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss) · Phase 2 · not yet recruiting
NCT07533019 — A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo · Phase 2 · not yet recruiting
NCT07247357 — A Study of LY4064809 in Healthy Adult Chinese Participants · Phase 1 · completed
NCT07124013 — A Study of Olomorasib (LY3537982) in Healthy Japanese Participants · Phase 1 · completed
NCT07030127 — A Study of LY3985863 in Healthy Participants · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02144272 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Eli Lilly and Company
Last refreshed: 15 July 2015

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02144272.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing